Cargando…

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma

Natural killer (NK) cells are the key cells of the innate immune system that share many characteristics with T lymphocytes; their activation, however, is based on the integration of a range of activatory and inhibitory signals via receptors recognizing recurrent pathogen-associated molecular pattern...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seymour, Frances, Cavenagh, Jamie D., Mathews, Janet, Gribben, John G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631618/ https://www.ncbi.nlm.nih.gov/pubmed/35834731 http://dx.doi.org/10.1182/bloodadvances.2022007905

Ejemplares similares

The Increased Ratio of Blood CD56(bright) NK to CD56(dim) NK Is a Distinguishing Feature of Primary Sjögren's Syndrome
por: Ming, Bingxia, et al.
Publicado: (2020)

Oncolytic virus treatment differentially affects the CD56(dim) and CD56(bright) NK cell subsets in vivo and regulates a spectrum of human NK cell activity
por: Wantoch, Michelle, et al.
Publicado: (2022)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
por: Pouleau, Blandine, et al.
Publicado: (2023)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
por: Perez de Acha, Olivia, et al.
Publicado: (2023)

Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020)

CD56(dim)CD16(dim) Natural Killer (NK) Cells: The Forgotten Population
por: Zimmer, Jacques
Publicado: (2020)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

CD34(+)CD19(−)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
por: Bueno, Clara, et al.
Publicado: (2022)

Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures
por: Mardanian, Farahnaz, et al.
Publicado: (2015)

Loss of CCR7 Expression on CD56(bright) NK Cells Is Associated with a CD56(dim)CD16(+) NK Cell-Like Phenotype and Correlates with HIV Viral Load
por: Hong, Henoch S., et al.
Publicado: (2012)

Human CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset
por: Amand, Mathieu, et al.
Publicado: (2017)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Human Natural Killer Cell Maturation Defect Supports In Vivo CD56(bright) to CD56(dim) Lineage Development
por: Domaica, Carolina Inés, et al.
Publicado: (2012)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells
por: Michelozzi, Ilaria M., et al.
Publicado: (2022)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies
por: Ang, Zhiwei, et al.
Publicado: (2023)

Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation
por: Landy, Emily, et al.
Publicado: (2023)

Reduction of the CD16(−)CD56(bright) NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination
por: Peng, Huiyun, et al.
Publicado: (2023)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

CD56(dim)CD16(high) and CD56(bright)CD16(−) cell percentages associated with maximum knee extensor strength and incidence of death in elderly
por: Senpuku, Hidenobu, et al.
Publicado: (2016)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
por: Philippon, Camille, et al.
Publicado: (2023)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

The identification of TCF1(+) progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
por: Tabanelli, Valentina, et al.
Publicado: (2022)

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
por: Perriello, Vincenzo Maria, et al.
Publicado: (2022)

Expansion of CD56(dim)CD16(neg) NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients
por: Casado, José L., et al.
Publicado: (2021)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

The phenotype of CD3–CD56(bright) and CD3–CD56(dim) natural killer cells in systemic lupus erythematosus patients and its relation to disease activity
por: Soelistyoningsih, Dwi, et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_etftuqejbpjuqitvhs6erd605a